Acadian Asset Management
VERV

Acadian Asset Management’s Verve Therapeutics VERV Stock Holding History

Acadian Asset Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-30,803
Closed -$140K – 1844
2025
Q1 		$140K Buy
30,803
+17,186
+126% +$115K ﹤0.01% 1305
2024
Q4 		$76K Sell
13,617
-179,149
-93% -$1.01M ﹤0.01% 1402
2024
Q3 		$932K Buy
+192,766
New +$1.12M ﹤0.01% 929

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Acadian Asset Management's VERV Position: Q2 2025 in Review

Acadian Asset Management sold out of Verve Therapeutics (VERV) in Q2 2025, closing a stake of 30,803 shares — an estimated $140K sold.

Acadian Asset Management first reported a position in VERV in Q3 2024 and held it in 3 quarters. The position peaked at $932K in Q3 2024. 175 funds tracked by Wall St. Rank hold VERV as of Q2 2025.

  • Acadian Asset Management reported no remaining Verve Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Acadian Asset Management sold 30,803 Verve Therapeutics shares in Q2 2025, an estimated $140K.
  • Acadian Asset Management first reported a position in Verve Therapeutics in Q3 2024 and held it in 3 quarters.
  • Acadian Asset Management's Verve Therapeutics position peaked at $932K in Q3 2024.
  • 175 funds tracked by Wall St. Rank held Verve Therapeutics as of Q2 2025.

Based on Acadian Asset Management's 13F filing for Q2 2025, filed 7 Aug 2025.